New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - alimemazine tartrate 0.6%{relative};  ; alimemazine tartrate 0.6%{relative} - syrup - 30 mg/5ml - active: alimemazine tartrate 0.6%{relative}   excipient: ascorbic acid citric acid as monohydrate ethanol prunus armeniaca purified water sodium benzoate sodium citrate dihydrate sodium metabisulfite sodium sulfite sucrose active: alimemazine tartrate 0.6%{relative} excipient: ascorbic acid citric acid monohydrate ethanol prunus armeniaca purified water sodium benzoate sodium citrate dihydrate sodium metabisulfite sodium sulfite sucrose - · urticaria

Ireland - Inggeris - HPRA (Health Products Regulatory Authority)

allergan pharmaceuticals ireland - botulinum toxin type a - powder for solution for injection - 4 allergan units - other muscle relaxants, peripherally acting agents; botulinum toxin

Malta - Inggeris - Malta Medicines Authority

abbvie limited citywest business campus, dublin 24, ireland - powder for solution for injection - botulinum toxin type a 100 allergan units/0.1 millilitre - muscle relaxants

Malta - Inggeris - Malta Medicines Authority

abbvie limited citywest business campus, dublin 24, ireland - powder for solution for injection - botulinum toxin type a 50 allergan units/0.1 millilitre - muscle relaxants

Malta - Inggeris - Malta Medicines Authority

abbvie limited citywest business campus, dublin 24, ireland - powder for solution for injection - botulinum toxin type a 200 allergan units/0.1 millilitre - muscle relaxants

Israel - Inggeris - Ministry of Health

allergan israel ltd - bimatoprost - ophthalmic solution - bimatoprost 0.3 mg/ml - bimatoprost - bimatoprost - reduction of elevated intraocular pressure in chronic open angle glaucoma and ocular hypertension (as monotherapy or as adjunctive therapy to beta-blockers).

Singapura - Inggeris - HSA (Health Sciences Authority)

allergan singapore pte. ltd. - ophthalmology - for the temporary relief of burning, irritation and discomfort due to dryness of the eye or exposure to the wind or sun. it may also be used as protectant against further irritation.

Singapura - Inggeris - HSA (Health Sciences Authority)

allergan singapore pte. ltd. - epinastine hcl - solution, sterile - 0.05 % w/v - epinastine hcl 0.05 % w/v

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

allergan, inc. - progesterone (unii: 4g7ds2q64y) (progesterone - unii:4g7ds2q64y) - assisted reproductive technology crinone 8% is indicated for progesterone supplementation or replacement as part of an assisted reproductive technology ("art") treatment for infertile women with progesterone deficiency. secondary amenorrhea crinone 4% is indicated for the treatment of secondary amenorrhea. crinone 8% is indicated for use in women who have failed to respond to treatment with crinone 4%. crinone should not be used in individuals with any of the following conditions: - known sensitivity to crinone (progesterone or any of the other ingredients) - undiagnosed vaginal bleeding - liver dysfunction or disease - known or suspected malignancy of the breast or genital organs - missed abortion - active thrombophlebitis or thromboembolic disorders, or a history of hormone-associated thrombophlebitis or thromboembolic disorders crinone ® 4% and crinone ® 8% ("kri-noan") (progesterone gel) for vaginal use only you will need the following supplies: see figure a. step 1.  remove the applicator from the sealed wrapper. - open the sealed wrapper and remove the applicator. do not remove the twist-off cap at this time. see figure b. step 2. insert the plunger into the open end of the applicator. see figure c.   - hold the applicator on each side and push the plunger into the applicator until the plunger snaps into place. - you will see about 1 inch of the plunger outside of the applicator. step 3. remove the cap. see figures d and e. - remove the cap from the tip of the applicator by twisting it counterclockwise.  - do not push the plunger while you are removing the cap. this could cause some gel to come out. step 4. prepare to insert the applicator. see figure f. choose the position that is most comfortable for you. for example, lying down on your back with your knees bent. step 5. insert the applicator. see figure g. - after you are in a comfortable position, gently insert the rounded tip of the applicator into your vagina. step 6. push the plunger. see figure h. - while the applicator is inserted in your vagina, push the plunger to release the gel into your vagina. step 7. remove the applicator from your vagina and throw it away in your household trash. - it is normal for a small amount of gel to be left in the applicator. you will still get the right dose of medicine. this instructions for use has been approved by the u.s. food and drug administration. rx only for all medical inquiries contact: allergan usa, inc. irvine, ca 92612 1-800-678-1605 distributed by: allergan usa, inc. irvine, ca 92612 content updated: june 2017 © 2017 allergan. all rights reserved. crinone® is a registered trademark of allergan sales, llc. allergan® and its design are trademarks of allergan, inc. product of the netherlands. 73343us10

Armenia - Inggeris - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

vetprom ad - desloratadine - solution oral - 0.5mg/ml